4 Biotech Stocks Investors Should Watch in 2026

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.

Zacks Investment Research • Jun 5, 2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 353,000 shares of common stock to twenty new employees under the Company's 2024 Induc.

Business Wire • Jun 4, 2026

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed efficacy and safety results from RINGSIDE, the global, randomized, double-blind, placebo-controlled Phase 3 trial of varegacestat in patients with progressing desmoid tumors. The data are being presented today in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual.

Business Wire • May 30, 2026

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webca.

Business Wire • May 27, 2026

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update. “This quarter reflects the progress we are making in building Immunome into a multi-program targeted oncology company,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “The NDA submission for v.

Business Wire • May 12, 2026

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. “The varegacestat NDA submission marks an important milestone for Immunome. It r.

Business Wire • Apr 29, 2026

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3, randomized, placebo-controlled trial of varegacestat in patients with progressing desmoid tumors, has been selected for presentation in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 2.

Business Wire • Apr 21, 2026

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward prior highs.

FXEmpire • Apr 14, 2026

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026. This sale represented 30.02% of Higgins's holdings at the time.

The Motley Fool • Apr 4, 2026

Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research • Apr 1, 2026